Learn more in our training program.
Join our membership network.
Attend our events and collaborate.
Add your voice to our policy matters.
Get involved in our genetic registry.
Donate to our cause.
The Latino Cancer Institute (TLCI) is a nationwide community and research network dedicated to solving the issues and burden of Latino cancer.
Heart disease has surpassed cancer as the leading cause of death among Hispanics/Latinos in the U.S. However, cancer remains a major health concern, accounting for approximately 17% of deaths. Through public education, community resources, and improved access to care, survival rates continue to improve.
Breast cancer remains the most commonly diagnosed cancer and the leading cause of cancer death among Hispanic/Latina women. Additionally, cervical cancer rates continue to pose a serious threat to Latinas. In the fall 2024, The Latino Cancer Institute hosted a Virtual Friday Forum Series, bringing together leading voices in the field to discuss the latest research findings and promising interventions.
Lung cancer continues to be the leading cause of cancer death among Hispanic/Latino men. While smoking rates are lower among Latinos compared to other groups, targeted prevention efforts and early detection remain critical.
The Latino Cancer Institute is committed to reducing the burden of cancer in Latino communities through advocacy, research, and community-driven solutions. Learn more about us.
For over 20 years, Founder Ysabel Duron has played a vital role in bringing together those dedicated to making a difference in the Latino cancer landscape. From cancer community workers and caregivers to international medical researchers and policymakers, Ysabel has forged important alliances in a field crowded with many competing interests and agendas.
It takes a savvy insider who has traveled this terrain far and wide to help the Latino cancer community at-large continue changing the landscape. TLCI offers the definitive road map.
There are currently no upcoming events.
The Latino Cancer Institute acts as a network for agencies, linking members to share knowledge and best practices. Connecting colleagues, peers and institutions is critical to The Institute’s ongoing mission to amplify and disseminate outstanding work in the cancer arena, and to support one another.
The Latino Cancer Institute provides opportunities to network, learn and collaborate with stakeholders in the cancer landscape including Latino cancer researchers.
The Latino Cancer Institute leverages our united voice at the national table to advance Latino cancer concerns including education, services, funding, and research. Our aim is to be heard, understood and included in any proposed policy.
As a nonprofit organization, we rely on philanthropy and grants in our mission to support other agencies. Your funding allows us to continue the development of new programs and tools we can share with those making a difference in the lives of Latino cancer patients, survivors, and their caregivers.
Researchers have developed Deep Nanometry, an analytical technique combining advanced optical equipment with a noise removal algorithm based on unsupervised deep learning. Deep Nanometry can analyze nanoparticles in medical samples at high speed, making it possible to accurately detect even trace amounts of rare particles. This has proven its potential for detecting extracellular vesicles indicating early signs of colon cancer, and it is hoped that it can be applied to other medical and industrial fields.
Researchers have developed a powerful computational tool, named iDOMO, to improve the prediction of drug synergy and accelerate the development of combination therapies for complex diseases. The study highlights iDOMO's ability to identify synergistic drug combinations using gene expression data, outperforming existing methods.
In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells, researchers have identified a vulnerability that opens the door to new treatments.
Scientists have discovered a novel subset of cancer-fighting immune cells that reside outside of their normal neighborhood -- known as the tertiary lymphoid structure -- where they become frustratingly dysfunctional when in close contact with tumors.
Clinical research suggests that combining a novel agent called navtemadlin with DNA-damaging chemotherapy for the treatment of glioblastoma, a form of brain cancer, could increase efficacy. Navtemadlin is an MDM2 inhibitor that can help to kill cancer cells by boosting the activity of p53, a protein that controls cell growth and induces cell death in response to DNA damage. In lab experiments, the researchers found that navtemadlin was one of the best drugs at killing glioblastoma cells with intact, non-mutant p53.
Breast cancer incidence trends in U.S. women under 40 vary by geography and supports incorporating location information with established risk factors into risk prediction, improving the ability to identify groups of younger women at higher risk for early-onset breast cancer.
